Ask most practitioners what causes hair loss and the answer starts — and often ends — with dihydrotestosterone. DHT is real, the evidence is solid, and the follicle miniaturization pathway is well mapped. But for a substantial portion of patients presenting with diffuse thinning, pattern loss, or unexplained shedding, DHT is either a secondary player or completely irrelevant. The primary driver is somewhere else in the endocrine system.
Thyroid hormones, cortisol, estrogen, and the androgen excess patterns seen in PCOS each reach the hair follicle through distinct receptor systems, affect different phases of the cycle, and produce clinically recognizable — but frequently misread — presentations. Understanding these mechanisms changes how you assess, how you refer, and how you set expectations with patients who aren't responding to standard androgenic protocols.
This is a breakdown of what the peer-reviewed literature actually shows across all four of those hormonal pathways.
The Follicle as an Endocrine Target
Before mapping the individual hormones, it's worth establishing something fundamental: the hair follicle is not a passive bystander in systemic hormonal shifts. It is an active endocrine target with receptors for thyroid hormones, glucocorticoids, estrogens, and androgens. It also produces its own local hormones and can convert circulating precursors. The follicle responds to systemic hormonal status in real time — which is both why hair loss can be an early sign of endocrine dysfunction and why correcting the underlying imbalance is often the only durable path to recovery.
Hair follicles express receptors for thyroid hormones, glucocorticoids, estrogen, and androgens simultaneously. Disruption of any one of these systems can alter follicle cycling — through distinct and sometimes competing pathways. In women especially, it is common for two or more hormonal disruptions to co-exist.
Thyroid Hormones: The Cycle Regulator
Thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — are required for normal anagen progression. The follicle expresses thyroid hormone receptors in the dermal papilla, the outer root sheath, and the hair matrix. When circulating T3 and T4 are outside the optimal range in either direction, follicle cycling is disrupted.
In hypothyroidism, the characteristic presentation is diffuse telogen effluvium — the follicle enters the resting phase prematurely and stays there. A 2024 retrospective study found that 34% of hypothyroid patients experienced severe hair loss, and average hair loss severity scores were significantly higher in the hypothyroid group compared to euthyroid controls. The presentation can mimic androgenetic alopecia but typically lacks the temporal recession pattern and responds poorly to minoxidil unless the thyroid is corrected first.
Hyperthyroidism produces a different texture problem alongside shedding — hair becomes fine and silky rather than coarse, and loss is again diffuse rather than patterned. The key clinical indicator in both directions is the diffuse quality of the loss, the involvement of non-scalp hair (eyebrows, body hair), and the absence of trichoscopic signs typical of androgenetic miniaturization.
A comprehensive review of the cellular and molecular mechanisms linking thyroid dysfunction to hair loss. The authors detail how thyroid hormone receptors in the dermal papilla and outer root sheath regulate anagen entry and duration — and how both hypothyroid and hyperthyroid states produce distinct disruptions to this signaling. The review also covers the emerging evidence linking autoimmune thyroid disease to alopecia areata pathogenesis.
Read on PubMed Central →The Autoimmune Overlap
The thyroid-hair loss relationship gets significantly more complex when autoimmune thyroid disease enters the picture. Hashimoto's thyroiditis and Graves' disease both involve immune mechanisms that appear to share pathogenic pathways with alopecia areata. CD8+ lymphocyte infiltration, interferon-mediated immune activation, and anti-hair follicle autoantibodies have all been documented in patients who carry both conditions.
A 2024 Mendelian randomization study — which used genetic variants as proxies to establish causality rather than mere association — found a statistically significant causal link between hypothyroidism and alopecia areata onset (OR 1.34, 95% CI 1.16–1.56, p = 0.0001). The same study found no clear causal relationship between hypothyroidism and androgenetic alopecia, which is a meaningful distinction for workup purposes.
Using bidirectional two-sample Mendelian randomization, this study established that hypothyroidism causally increases the risk of alopecia areata onset. Critically, this causal signal was present for AA but not for AGA, suggesting distinct endocrine pathways underlie these two forms of hair loss. Thyroid antibody screening in AA patients — already common in dermatology — now has a stronger causal justification.
Read full study →Cortisol: The Stem Cell Suppressor
The relationship between psychological stress and hair loss has been dismissed for decades as anecdotal. That position became harder to hold after a 2021 Nature study out of Harvard mapped the exact molecular mechanism — and it turns out cortisol hits the follicle at one of the most fundamental levels possible: the stem cell activation signal.
The study, led by Ya-Chieh Hsu's lab, found that corticosterone (the rodent equivalent of human cortisol) acts on dermal papilla cells to suppress the expression of Gas6 — growth arrest specific 6 — a secreted signaling molecule that normally activates quiescent hair follicle stem cells and initiates anagen entry. Under chronic stress conditions, elevated corticosterone keeps Gas6 suppressed, which keeps the stem cells locked in prolonged quiescence. The follicles don't die. They just don't wake up.
This Harvard Stem Cell Institute study is the clearest mechanistic account of how stress hormones inhibit hair growth at the stem cell level. By restoring Gas6 expression in adrenalectomized and chronically stressed mice, the researchers demonstrated that Gas6 suppression is the primary mechanism — not a secondary effect — of cortisol-induced follicle quiescence. Restoring Gas6 reactivated the stem cells and resumed hair cycling even in the presence of elevated stress hormones.
Read on PubMed →In human clinical terms, this mechanism produces the presentation most practitioners recognize as telogen effluvium — diffuse shedding that begins two to three months after a significant stressor. The delay reflects the time between follicle arrest and the physical shedding of the hair shaft. The stressor can be psychological (grief, burnout, relationship breakdown), physiological (surgery, illness, childbirth), or both simultaneously — which is common and clinically important.
Chronic Stress and AGA Progression
A 2024 clinical study (PMC11514570) added another layer: chronic psychological stress doesn't just cause telogen effluvium — it also appears to accelerate androgenetic alopecia progression and reduces the treatment response to minoxidil. The study found significantly elevated cortisol levels throughout the day in the stress group, along with lower levels of neurotrophic factors (BDNF, NGF, GDNF), reduced hair diameter and density, and more severe AGA grading. After one year of treatment with 5% minoxidil, efficacy was lower and AGA progression was more pronounced in the stress group compared to controls.
Telogen effluvium from cortisol elevation typically resolves on its own once the stressor passes — but resolution can take 6–12 months, and incomplete recovery can overlap with the early stages of androgenetic alopecia in vulnerable patients. Identifying and addressing the stressor is therapeutically meaningful, not just supportive.
The 2025 JAAD Reviews synthesis of this literature also highlights the role of substance P — a neuropeptide released by peripheral nerve endings in the scalp under stress — in generating neurogenic perifollicular inflammation. Substance P activates mast cells, which release histamine and TNF-α, disrupting the follicle's immune privilege. This mechanism connects the stress-hair loss pathway directly to inflammatory alopecia, not just telogen effluvium.
Estrogen: The Protective Signal
Estrogen's role in hair biology is almost exclusively protective during reproductive years, and its decline — whether through menopause, postpartum hormonal shifts, or endocrine disruption — removes that protection in ways that are still being fully characterized.
The follicle expresses both estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), and circulating estradiol binds these receptors in the dermal papilla and outer root sheath. Estradiol extends anagen duration, stimulates the production of growth factors critical to follicular keratinocyte proliferation, and — crucially — upregulates aromatase activity in the scalp, which converts androgens to estrogens locally. This means estrogen doesn't just protect the follicle directly; it also reduces the local androgenic environment that drives miniaturization.
This review proposes that follicle senescence in menopausal women is not simply a downstream consequence of systemic estrogen loss — it may involve a parallel decline in the follicle's own estrogen metabolism, including changes in ER responsiveness and local aromatase activity. The authors describe a "follicle menopause" hypothesis that can occur independent of and sometimes preceding clinical menopause, driven by genetic factors, microbiome changes, and individual receptor sensitivity variations.
Read on PubMed Central →Postpartum Shedding and Menopausal Loss
Two estrogen-decline states are worth distinguishing clinically. Postpartum telogen effluvium is driven by the dramatic estrogen drop following delivery — estrogen levels that were artificially elevated throughout pregnancy suddenly normalize, and follicles that were held in an extended anagen synchronously enter telogen. The result is diffuse shedding that typically peaks at three to four months postpartum. This is physiologic and usually self-limiting, though it can be severe enough to be frightening for patients.
Menopausal hair loss is a slower, progressive process that more closely resembles androgenetic alopecia in its presentation — frontal thinning, widened part, decreased density across the crown — because the loss of estrogen-mediated androgen conversion tips the local scalp environment toward a more androgenic state even without any change in circulating androgen levels. A 2023 pilot study examining estradiol replacement therapy in postmenopausal women with FPHL found improvements in frontal hairline appearance and hair anchoring strength (plucking resistance), though the sample size was small and replication in larger trials is still needed.
A pilot study in postmenopausal Japanese women with FPHL found that estradiol HRT improved frontal hairline appearance and increased plucking resistance — a proxy for hair anchoring strength and follicle structural integrity. The findings are consistent with the proposed mechanism of estrogen protecting anagen duration, but the pilot design requires replication before clinical recommendations can be generalized.
Read on PubMed Central →PCOS: When Androgen Excess Isn't What You Think
Polycystic ovary syndrome is the most common endocrine disorder in reproductive-age women, affecting an estimated 5–15% of this population. Hair loss in PCOS presents as female pattern hair loss — frontal thinning with preserved frontal hairline in milder cases, more diffuse crown thinning in severe cases — and is driven by androgen excess, though the relationship between measured androgen levels and hair loss severity is far more complex than most practitioners realize.
Androgenic alopecia affects approximately 22% of women meeting PCOS diagnostic criteria, and it co-occurs with other hyperandrogenic manifestations including hirsutism and acne. However, FPHL can be present in PCOS patients with completely normal serum testosterone and DHEA-S levels — because the pathogenesis involves local scalp 5α-reductase activity and androgen receptor sensitivity, not just circulating androgen concentrations. This creates a clinical situation where the labs look normal but the follicles are still responding to androgens.
Isolated FPHL in the absence of other hyperandrogenic signs (acne, hirsutism, menstrual irregularity) does not require a PCOS workup — the AE-PCOS Society consensus is that normal-androgen FPHL should not be automatically classified as androgen excess. But FPHL in a patient who also has irregular cycles and acne warrants hormonal screening even when the androgens come back within reference range.
The Lab-Presentation Disconnect
A 2019 report from the Androgen Excess and PCOS Society — still the most cited reference on this topic — specifically addresses the lab-presentation gap: assessment of androgen excess is mandatory in all patients with FPHL, but a normal result does not rule out androgen-mediated pathology at the follicle level. The local conversion of DHEA-S to active androgens by scalp keratinocytes, the differential expression of 5α-reductase type 1 versus type 2 across scalp regions, and individual variation in androgen receptor density all contribute to presentation that doesn't correlate cleanly with serum levels.
This multidisciplinary consensus established the clinical evaluation framework for FPHL in the context of androgen excess. Key conclusions: androgen screening is mandatory in all FPHL patients; isolated FPHL without other hyperandrogenic signs does not equal androgen excess; and treatment decisions should integrate clinical presentation, hormonal context, and patient reproductive status. Anti-androgen therapy (spironolactone) is appropriate for androgen-excess FPHL; in normal-androgen FPHL the evidence is weaker.
Read on PubMed →Treatment Evidence in PCOS-Related Hair Loss
For patients with confirmed androgen excess, spironolactone — an aldosterone antagonist with androgen receptor blocking activity — has the strongest evidence base for FPHL management. A 2023 systematic review and meta-analysis (PMC10502763) found that approximately 43% of women with FPHL noticed improvement on spironolactone alone, rising to as high as 66% with combination therapy (typically minoxidil plus spironolactone). The treatment timeline is long: most patients need 6–12 months before visible results emerge, which is important to communicate at initiation.
When Hormones Overlap
The clinical reality is that these four hormonal pathways rarely operate in isolation. A perimenopausal woman presenting with progressive hair thinning may be experiencing the combined effects of declining estrogen, elevated cortisol from life stress, and subclinical hypothyroidism — all simultaneously reducing follicle resilience through different mechanisms. A young woman with PCOS may also have thyroid autoimmunity, which is more common in androgen-excess states than in the general population.
This is why a single-axis approach — running only a testosterone panel, or only treating for DHT — frequently produces incomplete results. A systematic hormonal screen in women with diffuse or pattern hair loss should include TSH (and free T4 if TSH is borderline), free and total testosterone, DHEA-S, sex hormone binding globulin, and fasting insulin. Cortisol assessment is more contextual but clinically relevant when the history suggests a precipitating stressor or when the shedding pattern is acute and diffuse.
Hair loss is frequently the presenting complaint that leads to the diagnosis of subclinical hypothyroidism, early PCOS, or perimenopause. The follicle is sensitive enough to systemic hormonal shifts that it often signals the problem before the patient has connected the dots — or before a GP has ordered the relevant labs. Your trichoscopy and clinical assessment may be the first piece of the diagnostic puzzle.
The Bottom Line for Practitioners
DHT is not the whole story. Thyroid hormones regulate anagen duration directly through follicular receptors, and both hypo- and hyperthyroidism produce diffuse telogen effluvium — with autoimmune thyroid disease carrying a causally supported link to alopecia areata. Cortisol suppresses hair follicle stem cell activation via Gas6 inhibition, keeping follicles in prolonged quiescence — a mechanism now documented at the molecular level in Nature. Estrogen extends anagen and reduces local androgenicity; its decline in menopause and postpartum produces clinically recognizable but mechanistically distinct presentations. And PCOS-related hair loss often operates at the local follicle level despite normal serum androgen labs, making clinical context and SHBG levels as important as absolute androgen values. Treating the hormone — not just the hair — is where durable outcomes live.